文献速递造血干细胞移植与细胞治疗浆细胞疾病

单倍体造血细胞与肾脏联合移植治疗血液肿瘤合并终末期肾病

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure.
PubMed 文献 · Blood · 2019-05-31

麻省总医院开展单倍体供者同期造血细胞与肾脏移植试点试验,6例受者中5例采用氟达拉滨、环磷酰胺及全身照射预处理,GVHD预防含移植后环磷酰胺、他克莫司及吗替麦考酚酯。1例死于氟达拉滨神经毒性并发症,后续降低氟达拉滨剂量并加强透析后未再出现神经毒性。12个月内无2-4级急性GVHD,1例中度慢性GVHD;4/6例存活且无疾病复发及肾脏排斥。

要点

  • 单倍体供者同期HCT/肾脏移植在6例血液肿瘤合并终末期肾病患者中可行。
  • 1例死于氟达拉滨神经毒性,降低剂量并加强透析后未再发生。
  • 12个月内无2-4级急性GVHD,1例中度慢性GVHD;4/6例存活无复发及肾脏排斥。

核心结论

  • 单倍体供者同期造血细胞与肾脏移植在6例血液肿瘤合并终末期肾病患者中可行,4/6例存活且无疾病复发及肾脏排斥。

研究设计与样本

  • 麻省总医院开展的试点试验,6例受者接受单倍体供者同期HCT/肾脏移植,其中5例预处理为氟达拉滨、环磷酰胺及全身照射。
  • GVHD预防包括移植后环磷酰胺、他克莫司及吗替麦考酚酯;试验注册号NCT01758042。

主要发现

  • 1例患者死于氟达拉滨神经毒性并发症;后续接受较低氟达拉滨剂量及更强化透析的患者未观察到神经毒性。
  • 12个月内无2-4级急性GVHD病例,1例中度慢性GVHD。
  • 1例多发性骨髓瘤患者在HCT后30个月复发并于移植后4年死亡;4/6例存活,无疾病复发且长期无肾脏排斥存活。

临床怎么用

  • 对血液肿瘤合并终末期肾病患者,可考虑单倍体供者同期HCT/肾脏移植,但需注意氟达拉滨神经毒性,可采用较低剂量及强化透析。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

At Massachusetts General Hospital, we pioneered simultaneous hematopoietic cell (HCT)/kidney transplantation from HLA-identical related donors for the treatment of hematological malignancies with end-stage renal failure. We have now extended this to HLA-haploidentical donors in a pilot trial. Six recipients, 5 of whom were conditioned with fludarabine, cyclophosphamide, and total-body irradiation, underwent combined HCT/kidney transplantation from haploidentical donors; graft-versus-host disease (GVHD) prophylaxis included post-HCT cyclophosphamide, tacrolimus, and mycophenolate mofetil. One patient died as a result of complications of fludarabine neurological toxicity. No neurological toxicity was observed in subsequent patients who received lower fludarabine doses and more intense postfludarabine dialysis. There were no cases of grade 2 to 4 acute GVHD and 1 case of moderate chronic GVHD by 12 months. One patient experienced relapse of multiple myeloma at 30 months after HCT and died 4 years posttransplantation. Overall, 4 of 6 patients remain alive, without disease relapse and with long-term renal rejection-free survival. This trial was registered at www.clinicaltrials.gov as #NCT01758042.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chen YB, Elias N, Heher E, et al. Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. Blood. 2019. PMID: 31151984. doi:10.1182/blood.2019000775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。